Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Recruiting

Phase 3

DalcetrapibEffect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Sponsor:

DalCor Pharmaceuticals

Code:

NCT05918861

Conditions

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 45+

Healthy Volunteers: Not accepted

Interventions

Dalcetrapib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by DalCor Pharmaceuticals on 2025-04-24.